STEVENSON, Md., Dec. 9, 2014 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Aeterna Zentaris, Inc. ("Aeterna Zentaris" or the "Company") (Nasdaq: AEZS ) securities during the period between October 18, 2012 and November 6, 2014, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until January 12, 2015 to seek appointment as lead plaintiff.
If you have suffered a loss from investment in Aeterna Zentaris securities purchased on or after October 18, 2012 and held through the revelation of negative information during and/or at the end of the Class Period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at: http://www.browerpiven.com/currentsecuritiescases.html . You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company units during the Class Period. Brower Piven also encourages anyone with information regarding the Company's conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of their failure to disclose during the Class Period that because certain patients – those with confirmed growth hormone deficiency – were included in the results of the Company's Phase III clinical trial for its drug MACRILEN(TM), the results failed to meet the objectives of the Special Protocol Assessment agreed to with the FDA. According to the complaint, following the Company's November 6, 2014 announcement that it had received a Complete Response Letter indicating the FDA would not approve the Company's MACRILEN NDA and required a new confirmatory clinical trial to demonstrate the efficacy of MACRILEN as a diagnostic test for growth hormone, the value of Aeterna Zentaris shares declined significantly.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616
